QIAGEN Clinical Insight (QCI) Interpret identifies targeted therapy and clinical trials in hematological tumors
Hematological malignancies originating from hematopoietic and lymphoid tissue are complex heterogeneous diseases characterized by distinct clinicopathological features and molecular alterations. The heterogeneity of leukemia and lymphoma has presented massive challenges for identifying the appropriate treatment for each patient. Advances in next-generation sequencing (NGS) have presented unique treatment opportunities beyond standard of care and chemotherapy. QIAGEN® Clinical Insight (QCI™ Interpret) is a web-based application for the annotation, classification, and reporting of clinically actionable variants from NGS data in clinical genomics laboratories.